ICU Medical (NASDAQ:ICUI) Updates FY24 Earnings Guidance

ICU Medical (NASDAQ:ICUI) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $5.40-5.70 for the period, compared to the consensus earnings per share estimate of $5.24.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Thursday, September 12th. Jefferies Financial Group began coverage on shares of ICU Medical in a research report on Monday, October 14th. They set a “hold” rating and a $183.00 price objective on the stock. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Thursday, October 10th. Raymond James upped their target price on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Finally, KeyCorp boosted their target price on shares of ICU Medical from $147.00 to $198.00 and gave the company an “overweight” rating in a research report on Tuesday, October 15th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.25.

ICU Medical Stock Down 0.1 %

NASDAQ ICUI traded down $0.26 during trading on Tuesday, hitting $178.01. 267,344 shares of the company traded hands, compared to its average volume of 273,286. The business has a fifty day simple moving average of $175.56 and a 200 day simple moving average of $141.16. The company has a current ratio of 2.41, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $4.35 billion, a P/E ratio of -61.05 and a beta of 0.66. ICU Medical has a 12 month low of $79.85 and a 12 month high of $188.53.

Insider Transactions at ICU Medical

In related news, VP Daniel Woolson sold 2,502 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the transaction, the vice president now directly owns 13,107 shares of the company’s stock, valued at $2,139,324.54. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, VP Daniel Woolson sold 2,502 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the sale, the vice president now owns 13,107 shares in the company, valued at $2,139,324.54. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction on Friday, November 1st. The shares were sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the transaction, the chief executive officer now owns 104,593 shares in the company, valued at approximately $17,973,261.12. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,502 shares of company stock worth $8,445,976 in the last three months. Insiders own 6.70% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.